Is ADHD Overdiagnosed? The Better Question Is Whether People Are Being Assessed Properly

The phrase “ADHD overdiagnosis” gets searched a lot because rising diagnosis numbers can look alarming from the outside. But higher diagnosis rates do not automatically mean ADHD is being diagnosed too freely. In the UK, the latest high-quality reviews are actually pointing in the opposite direction: the 2025 and 2026 work around the NHS England ADHD Taskforce and the recent British Journal of Psychiatry editorial both say there is no robust evidence that ADHD is overdiagnosed in the UK and that the bigger population-level problem appears to be under-recognition and under-diagnosis. 

A spilled pill bottle reveals a scattering of orange and white capsules on a vibrant orange background, symbolizing medicinal care and the importance of proper medication management.

That does not mean every assessment is flawless. It means the public debate is often framed badly. The Taskforce report says there is no evidence of an increase in the number of children in the population meeting ADHD criteria over time, while administrative diagnosis rates remain below expected prevalence. The same report also states that diagnosis must come from a full and thorough clinical assessment, not questionnaires alone. So the real concern is less “Are too many people getting diagnosed?” and more “Are people being assessed carefully, consistently, and to the right standard?” 

That distinction matters because both things can be true at once: ADHD can be underdiagnosed overall, while some people are also misdiagnosed through poor-quality assessment. The new BJPsych editorial makes exactly that point: it argues there is no evidence of overdiagnosis at population level in the UK, but warns that misdiagnosis may occur when assessments are low quality, national guidance is not followed, or differential diagnosis is poor. In other words, “overdiagnosis” is often the wrong label for what is really a quality-of-assessment problem. 

One reason the debate gets so heated is that diagnosis demand has risen sharply. In December 2025, the UK government launched an independent review into mental health, ADHD and autism services, explicitly pointing to rising demand and asking what is driving it. But rising demand does not prove a disorder is fashionable or fictional. It can also reflect better awareness, delayed identification, changing social demands, and long-standing unmet need. The Taskforce and the recent expert commentary both lean toward that interpretation rather than an “epidemic of overdiagnosis” narrative. 

There is also a strong reason to be cautious about overdiagnosis claims in adults, women and girls. A 2023 systematic review on ADHD in adult women found persistent patterns of missed and delayed diagnosis, and a 2025 Scientific Reports study described the harms of late diagnosis in women. Those findings fit a broader picture: some groups are much more likely to have been overlooked historically, so rising diagnosis numbers may partly represent services catching up rather than lowering the bar. 

At the same time, there are legitimate concerns about how some assessments are being delivered. The BMJ and the British Journal of General Practice have both raised concerns about outsourced or private ADHD assessments, especially when evaluation is rushed or incomplete. More recently, reporting in 2026 highlighted serious worries from clinicians about underregulated private pathways, including concerns about remote-only prescribing and assessments that do not consistently meet NHS standards. That does not prove ADHD is overdiagnosed across the country; it does suggest that variable assessment quality is a real risk, especially when long waits push people into fragmented private care. 

This is why the better question is not “Is ADHD overdiagnosed?” in the abstract. It is: Who is being assessed well, who is being missed, and who is being rushed through poor systems? That question is much more useful for patients, clinicians and employers. It also aligns with the practical reality that ADHD diagnosis should involve developmental history, current impairment, and proper differential diagnosis, as set out in the current NICE guideline on ADHD. 

For workplaces, the “overdiagnosis” debate can also become a distraction. If an employee is struggling with attention regulation, overwhelm, time management, memory, task initiation or communication, the immediate question at work is rarely “Has society diagnosed too many people?” The practical question is “What support would reduce disadvantage and help this person work well?” That is why a needs-led approach matters so much in practice. On Divergent Thinking’s workplace assessments page, the focus is on identifying friction, improving communication, and recommending practical changes in workflow, environment or support — not on forcing people to prove themselves through unnecessary scepticism.

There is a wider human cost too. The argument that ADHD is mostly being overdiagnosed can make genuinely struggling people feel fraudulent, dramatic or undeserving of help. The recent BJGP commentary argues that the under-versus-overdiagnosis framing can become divisive and obscure the more important point: people seeking diagnosis are often seeking explanations, support and a way to function better. That does not mean every diagnosis is correct. It does mean the public conversation should be careful not to confuse rising visibility with invalidity. 

So the clearest answer is this:

No, there is currently no robust evidence that ADHD is overdiagnosed at population level in the UK.

Yes, there are real concerns about misdiagnosis and poor-quality assessment in some pathways.

And yes, underdiagnosis — especially delayed or missed diagnosis — still appears to be the bigger systemic issue. 

If you want the practical, workplace side of this conversation rather than only the diagnostic debate, you can explore the Divergent Thinking blog, read more about workplace assessments and adjustment support, or browse the wider Divergent Thinking neuroinclusion offer. The most useful response to uncertainty is not stigma. It is better assessment, better support, and better design.